Showing results (331-340 of 348) with videos related to

Sort By:
Pageof 35
Urologic Oncology|April 4, 2026
Risk stratification of Ta high-grade non-muscle-invasive bladder cancer: Insights from a multicenter cohort studyPaolo Zaurito, Pietro Scilipoti, Mattia Longoni, et al.
Minerva Urology and Nephrology|April 23, 2026
Real-world multicenter adherence to international guidelines in the management of upper tract urothelial carcinoma: insights from the ROBUUST 2.0 RegistryMariaconsiglia Ferriero, Gabriele Tuderti, Flavia Proietti, et al.
World Journal of Urology|April 18, 2025
Combined neoadjuvant and adjuvant therapy versus adjuvant therapy in high-risk upper tract urothelial carcinoma: a propensity matched multicenter analysis (ROBUUST 2.0 International Collaborative Group)Ahmed Eraky, Reuben Ben-David, Gabriele Bignante, et al.
Urologic Oncology|March 3, 2026
Perioperative and oncologic outcomes of extirpative surgery for upper tract urothelial cancer in octogenariansTaibo Li, Stephan Brönimann, Ahmed Eraky, et al.
European Journal of Surgical Oncology : the Journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology|August 8, 2026
Oncological outcomes of radical nephroureterectomy with or without lymphadenectomy and neoadjuvant therapy in cN+ UTUC: Insights from the ROBUUST registryFrancesco Passaro, Roberto Contieri, Antonio Tufano, et al.
World Journal of Urology|September 2, 2025
Radical nephroureterectomy vs kidney sparing surgery for upper tract urothelial carcinoma in solitary kidney patients: a multi-institutional analysis of the ROBUUST 2.0 registryFrancesco Ditonno, Alessandro Veccia, Gabriele Bignante, et al.
Urology Practice|June 22, 2026
Metachronous contralateral recurrence in upper tract urothelial carcinoma: a multi-institutional competing-risks analysis from the ROBUUST 3.0 registryFrancesco Ditonno, Alessandro Veccia, Giacomo Musso, et al.
European Urology|May 23, 2018
Outcomes of Robot-assisted Partial Nephrectomy for Clinical T2 Renal Tumors: A Multicenter Analysis (ROSULA Collaborative Group)Riccardo Bertolo, Riccardo Autorino, Giuseppe Simone, et al.
World Journal of Urology|October 28, 2025
Real-world impact of cisplatin-based neoadjuvant chemotherapy on bladder cancer survival: a 20-year studyMario de Angelis, Francesco Pellegrino, Pietro Scilipoti, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|June 16, 2026
Surrogacy of Intermediate Clinical Endpoints for Overall Survival in Patients With Localized Muscle-Invasive Bladder CancerPietro Scilipoti, Mario de Angelis, Constance Thibault, et al.
Pageof 35